TRANSMITTAL OF INFORMATION DISCUSSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) OLD Docket No. 42830-00234											
In Re Ap	In Re Application Of: BLONDER et al.										
	Serial No.	Filing Da	te 40pm;	a K	Examin	, de	Group Art Unit				
09	9/888,235	June 22,	2001		Li, Bao Q.	MARK	1648				
		ICLE COMPOSIT	ION AND ME	THODS FO	OR DELIVERING		RECEIVED				
							OCT 3 1 2003				
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450											
			37 C	FR 1.97(b)	•						
1. 3	1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.										
			37 C	FR 1.97(c))						
2. 🗌	2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:										
	☐ the staten	nent specified in 37	CFR 1.97(e);								
		OR									
	☐ the fee se	t forth in 37 CFR 1	.17(p).				:				

TRANSMITTAL O	Docket No. 42830-00234									
In Re Application: I	BLONDER et al.	8 2003								
Serial No. Filing Date Examiner Group Art Unit 09/888,235 June 22, 2001 Li, Bao Q. 1648										
DELIVERY VEHICLE COMPOSITION AND METHODS FOR DELIVERING ANTIGENS AND OTHER DRUGS RECEIVE										
			OCT 3 1 2003							
	-	ment of Fee ects to pay the fee set forth in 37 C	TECH CENTER 1600 290							
□ A check in the amount of is attached. □ The Director is hereby authorized to charge and credit Deposit Account No. 50-1419 as described below. □ Charge the amount of □ Credit any overpayment. □ Charge any additional fee required. Certificate of Transmission by Facsimile* Certificate of Mailing by First Class Mail □ certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: Certificate of Mailing by First Class Mail Certify that this document and fee is being deposited on October 23, 203 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Signature Signature of Person Mailing Correspondence Lynn Pennywell										
Typed or Printed N	Name of Person Signing Certificate	Typed or Printed Name o	of Person Mailing Certificate							
*This certificate may only be used if paying by deposit account. Dated: October 25, 2003										
Ross E. Breyfogle, Esq. Reegistration No. 36,759 Marsh Fischmann & Brey 3151 South Vaughn Way, Aurora, Colorado 80014 (303) 338-0997 cc:	<u> </u>									

_					ATTY DOCKET NO. 42830-00234	SERIAL NO. 09/888,235							
INFORMATION DISCLOSURE CITATION (Use several/sheets if necessary)						BLONDER ET AL.							
		()	ise severaysneets ii necessa	(9 /) ∴		FILING		GROUP					
nrt 2 8 2003						06/22/01			1648				
			A. E. E.	<i>iij</i> u.s	. PATENT	DOCUMENTS							
*EXAMINER	DOCUMENT NOTES TO THE PARTY OF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE				
									-051	VED			
									ECEI	۷۲			
								Ö	CT 3 1	2003			
								TECH	CENTER	1600/29			
								12011					
	İ									-			
				FORE	IGN PATE	NT DOCUMENTS							
			DOCUMENT NUMBER	DATE		COUNTRY	SUBCLASS	TRANS YES	LATION NO				
			OTHER DOCUMEN			Title, Date, Pertinent I							
		Newman, M. J. et al., "Development of Adjuvant-Active Nonionic Block Copolymers"; Advanced Drug Delivery Reviews 32 (1998) 199-223.											
-		2.	Reed, C., "Pluronic Block Copolymers As Immunological Adjuvants", A Thesis Submitted For The Degree Of Doctor Of Philosophy, January 1993, Dept. of Parmaceutical Sciences, University of Strathclyde.										
EXAMINE	R		I			DATE CONSIDERED							
			ference considered, whether by of this form with next comm			ance with MPEP 609; Draw	line through o	citation if not in co	nformance	and not			

Form PTO-A820 (also form PTO-1449)

INFORMATION DISCROSURE CITATION (Use several sheets if new ssary)					ATTY DOCKET NO. 42830-00234			SE	SERIAL NO. 09/888,235				
					1	BLONDER ET AL.							
						FILING	/22/01		GF	ROUP 1	1648		
	—		ncī 2 8 2003 89	U.S	PATENT	DOCUMENTS	22/01		<u></u>		.048		
*EXAMINER	т—	$\overline{}$	DOCUMBLE ANNEES BY	<u> </u>	FAILN.						FILING DAT	TE	
INITIAL	₩	+	DOCUMBON AND RESERVE	DATE		NAME		CLASS		SUBCLASS	IF APPROPRIATE		
	1_									<u> </u>			
		\perp								RECE	VED		
									-	7606	V L		
										OCT 3 1	2003		
								T	FC	H CENTER	1600/29/	M	
		+							-	106111-	1000,20	/	
	 	+							-			P	
	\vdash	+	+				-+		-		•		
	├-	+								 			
	-	+-											
	 												
				FOREIG	GN PATE	ENT DOCUMENTS					•		
			DOCUMENT NUMBER	DATE		COUNTRY		CLASS		SUBCLASS	TRANSI YES	SLATION NO	
									\neg				
	\vdash	+							\dashv				
	-	+					+		\dashv				
	-	+					_		4			 	
	<u> </u>			(1 -1dim)	- 4504								
			OTHER DOCUMEN Spitzer, N. et al., "Long-T (1999) (1298-1300).			r, Title, Date, Per Against Leishmania				tic Peptide V	accine,"; V	accine 17	
	'	3.	(1999) (1298-1300).			B	· · · · · · · · · · · · · · · · · · ·	- <u>-</u>			., .		
	<u> </u>												
	'												
	'									·			
EXAMINER	R					DATE CONSIDERED							
			eference considered, whether			lance with MPEP 60	09; Draw line	e through		ation if not in cc	onformance	and not	
			py of this form with next comn				•					İ	